Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies
Misako Nagasaka+more
When patients with advanced metastatic NSCLC initially make their way into our medical oncology clinic, one of the first things we check for is the molecular pathology testing report, in […] Read more
Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD
Marcelo V. NegraoDr. Negrao is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center. Dr. Negrao has a diverse experience in […] Read more
Premonitions About Lung Cancer for the Next Decade
Ramón Rami-Porta, MDDaniel Kahneman, PhD, was awarded the Nobel Prize in 2002 for proving, among other things, that intuitions—even expert ones—fail and that formulas based on data fare better. Intuitions are more […] Read more
Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer
Ling Peng, MD, PhD+more
HER2 can be aberrantly expressed in NSCLC, caused by its mutation and/or amplification.1 Like in breast cancer, patients with NSCLC with somatic HER2 mutations rarely show concurrent gene amplification, highlighting […] Read more
Liquid Biopsy: The Key Weapon for Real-Time Monitoring of Patients With NSCLC
Christian Rolfo, MD, PhD, MBA, Drhc+more
Tissue still represents the “gold standard” biosource for molecular profiling of lung cancer. However, the use of tissue samples in clinical practice is associated with several technical and biological limitations. […] Read more
PD-L1 Blockade Reinvigorates Dendritic Cells for Antitumor Immunity
Wei Xu, MD, PhDIn reference to: Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12(534):eaav7431. Checkpoint blockade with PD-1 or PD-L1 […] Read more
Experts discuss how a global pandemic is putting pressure on traditional methods of research dissemination. A search on PubMed.gov for COVID-19 reveals 93,851 results as of Mid-January 2021. “To put […] Read more
Impactful Multidisciplinary Care Not Out of Reach in Community Settings
Leah LawrenceIn 2014 the IASLC, in collaboration with the American Thoracic Society and the European Respiratory Society, published a new classification of lung adenocarcinoma.1 The publication addressed new terminology and diagnostic […] Read more
CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients With Lung Cancer
Soon Ho Yoon, MD, PhD+more
The COVID-19 pandemic has caused more than 43.2 million cumulative cases and 1.16 million deaths, as of late October 2020. Approximately 1% of patients with COVID-19 have malignancy,1 and lung […] Read more
EGFR/ALK-Mutated NSCLC: Using Real-world Therapeutic Practices to Help Answer Real-world Therapeutic Questions
Shirish Gadgeel, MDILCN Editorial Group member Shirish M. Gadgeel, MD, is Chief of the Division of Hematology/Oncology at the Henry Ford Cancer Institute/Henry Ford Hospital. Dr. Gadgeel is currently working, in conjunction […] Read more